There is tremendous ferment in the field of epigenetics as the relationships between chromatin structure and DNA methylation patterns become clearer. Central to this activity is the realization that the 'histone code', which involves the post-translational modification of histones and which has important ramifications for chromatin structure, may be linked to the DNA cytosine methylation pattern. New discoveries have suggested that histone lysine 9 methylation is implicated in the spread of heterochromatin in Drosophila and other organisms. Very recently it has been found that histone lysine 9 methylation is also necessary for some DNA methylation in Neurospora and plants. There is therefore the possibility that these two processes are closely linked, suggesting ways in which DNA methylation patterns may be established during normal development. Understanding these processes is fundamental to understanding what goes awry during the process of aging and carcinogenesis where DNA methylation patterns become substantially altered and contribute to the malignant phenotype. Oncogene (2002) 21, 5358 -5360. doi:10.1038/sj.onc. 1205597
Keywords: epigenetics; DNA methylation; chromatic structure; silencing; tumor suppressor gene Advances in our understanding of the basic mechanisms by which gene silencing occurs at the chromatin and cytosine methylation levels have occurred simultaneously with the realization that the epigenetic silencing of tumor related genes has to be considered a third pathway to satisfy Knudson's hypothesis. Silencing can participate as one of two events necessary for the inactivation of a tumor suppressor gene and the full expression of the transformed phenotype. This review issue of, Oncogene, appears at a critical time in the development of the field of cancer epigenetics since it can serve as an important bridge between these two converging and exciting fields. The issue contains 13 articles, several of which are written by relative newcomers to the field in order to gain a fresh perspective of these developments.
The relationship between chromatin structure and cytosine methylation is the subject of the first article by Keith Robertson. He discusses how chromatin proteins interact with the DNA methyltransferases in setting up methylation patterns. Progress in the field of cancer epigenetics has been stymied by our failure to understand the basic mechanisms by which patterns are established. This paper suggests that we may be close to unraveling the interactions between DNA binding proteins and the methylation machinery.
The paper by Susan Clark and John Melki explores the mechanisms by which CpG islands are likely to become methylated during cancer development. They argue, in their review, that methylation is not the initial triggering event in gene silencing and in cancer, but rather that methylation of CpG islands is a consequence of prior gene silencing. This would mean that cytosine methylation in cancer has a similar role to the one it plays in maintaining the silencing of CpG island genes on the inactive X chromosome. This argument fits in nicely with current concepts regarding the need for changes in the histone code to be initiated before cytosine methylation follows. They argue that gene silencing is a critical precursor in cancer and that it changes the dynamic interplay between de novo methylation and demethylation of CpG islands thus tilting the balance to favor hypermethylation and the locking of chromatin in an inactive state.
The concept that methylation is a lock, rather than an initiator of silencing, is amplified in the paper by Mitch Turker. He proposes that gene silencing is a result of the spreading of methylation. Turker argues that gene silencing is not a single event but is instead a series of events beginning with a dramatic drop in transcription potential and ending with its complete cessation. He suggests that this transition is a chaotic process that ensures when transcription levels drop and DNA methylation begins spreading haltingly towards the promoter which is now less active in causing transcriptional initiation. According to Turker's views, silencing is stabilized when the promoter region is captured by the spread of DNA methylation into the region where transcription factors bind to ensure transcriptional initiation. Once again this paper argues that methylation is a secondary event which follows the gradual silencing and puts the final coup de graˆce on the silencing process.
The methylation signals are most likely interpreted by methyl CpG binding proteins which recognize and bind to the cytosine methyl groups protruding into the major groove of the DNA helix. The role of these methyl binding proteins in cancer is only now beginning to become unraveled and Igor Prokhortchouk and Brian Hendrich consider the part these proteins may play in several stages of tumor progression.
Melanie Erlich discusses the fact that cancerassociated DNA hypomethylation is as prevalent as cancer-linked hypermethylation, a fact which is often overlooked given our current focus on promoter hypermethylation and gene silencing. In fact, much of cancer genome is subject to undermethylation and this process occurs commonly in highly and moderately repeated DNA sequences including heterochromatic DNA repeats, dispersed retrotransposons and endogenous retroviral elements. The high frequency of this hypomethylation is consistent with an important role for DNA undermethylation in cancer formation and progression. Indeed, hypomethylation may directly affect karyotypic stability and might initiate altered heterochromatic-euchromatic interactions favoring oncogenesis.
Dominic Smiraglia and Christoph Plass next discuss the use of restriction landmark genomic scanning to detect aberrant methylation in cancer. This is only one of many methods available for studying epigenomics and has the advantage that it can detect regions of hypomethylation in addition to regions of hypermethylation. This method has already given us important information as to the genome-wide nature of changes which underlie tissue-specific alterations in different human cancers. For example, it is shown that methylation changes are more prevalent in certain types of cancers than others and quite a wide variability can exist in the methylation changes which occur in different specimens of the same cancer. Clearly the application of this scanning technology together with the candidate gene approaches which are discussed in some of the other chapters is very necessary for us to gain a complete understanding of the extent of the changes which underlie the malignant phenotype.
The application of these methodologies to study CpG island methylation in the promoters of genes involved in key cellular pathways is the subject of the paper by Manel Esteller. This paper, like the previous one, concentrates on the different patterns of methylation seen in different kinds of human cancer and clearly identifies patterns which are tumor type specific. As Esteller points out, careful functional and genetic studies will be necessary to determine which of these hypermethylation events are causal in the evolution of human cancers or merely passengers along the path to malignancy.
The review by Kyoung-Mee Kim and Darryl Shibata shifts gears, and explores the possibility of using the epigenetic marks imprinted on DNA as a result of cytosine methylation to track the evolution of stem cells in biological niches. They propose that one can use the binary code inherent in DNA methylation to construct a kind of bar code, which can track the evolution of cell niches. The clever use of the binary code to track stem cell dynamics is crucial to understanding the evolution of cancers which are likely to result from the transformation of such stem cells.
The paper by Jeffrey Tsou et al catalogs the changes in methylation which have been found in lung cancer a tumor which is responsible for the majority of cancer deaths worldwide. As these authors point out, the best opportunity for improving survival in long-term smokers is the use of screening techniques in high risk populations to detect the lung cancers at the earliest possible resectable stages. The recent literature has been replete with examples of hypermethylation of CpG islands in the promoter regions of more than 40 genes in lung cancer. Importantly, abnormally methylated alleles can be detected in patients' sputum and/or serum and the analysis of methylation patterns of multiple genes can be used to obtain complex DNA methylation signatures, which could provide a useful and highly specific tool for lung cancer diagnosis. While it is still far too early to know if these approaches would be of value in the early detection of lung cancer, further study is clearly justified in view of the fact that a large number of people smoke. Screening these individuals would be highly justified if it can be demonstrated that early detection does in fact result in increased survival.
Breast cancer is another tumor type in which multiple changes in methylation of cancer related genes have been reported. The paper by Martin Widschwendter and Peter Jones examines these changes in light of recent discoveries which have firmly established that at least six key pathways have to be inactivated or activated for a cell to fully acquire the malignant phenotype. The important point from the analysis of the literature is that almost all of the key players in the six pathways are known to be subject to methylation changes associated with the development of breast cancer. The review highlights how DNA methylation contributes to these events and outlines how the changes might be prevented/reverted or used as tags, for early detection of breast cancer or for the detection of premalignant changes.
The reversibility of methylation-induced gene silencing is a highly attractive clinical option for the treatment of cancer. Judith Christman describes how 5-azacytidine and 5-aza-2'-deoxycytidine interact with DNA methyltransferases after incorporation into DNA. She also discusses the need for new less toxic inhibitors. Adam Karpf and David Jones then explore the gamut of genes activated by treatment with 5-azanucleosides. Approaches utilizing microarrays have shown that the number of genes activated is less than what one would anticipate based upon knowledge of the number of genes subject to methylation silencing as shown by genome scanning technologies. Another important observation has been the finding that many of the genes activated in this way do not have CpG islands within their promoters. Thus, sorting out exactly how demethylating agents induce gene expression and the number of pathways activated by this approach, would be an important research area in years to come.
The final chapter by Laurie Jackson-Grusby outlines how many of the important questions related to human carcinogenesis can be approached by the use of appropriate mouse model systems. These approaches include an analysis of the role of DNA methylation in the process and are likely to be very important approaches not only in understanding the basic mechanisms by which cancer evolves but also in the design of new drugs to combat the initiation and progression of human disease.
These 13 chapters therefore capture several of the most exciting recent developments in this rapidly evolving field. It was not too long ago that the contribution of epigenetic silencing to human carcinogenesis was relatively underappreciated. Now that the basic mechanisms of the link between the histone and 5-methylcytosine codes are becoming clearer, and the full effect of methylation induced and reinforced silencing of tumor-related genes becomes known, epigenetics is attracting more attention. The marking of our DNA with methyl groups and the changes within these marks as we age and develop cancer, provides us with important new therapeutic options. Changed patterns can be detected with high sensitivity, they have prognostic information and can be reversed by appropriate drug treatment. These possibilities make cancer epigenetics a most exciting field of current translational research.
